Clinical Trial Update: A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of senicapoc (ICA-17043) in sickle cell disease patients, with or without hydroxyurea therapy, was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ICA-17043 (senicapoc)

Snippet

Sponsor: Icagen | Conditions: Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Status: TERMINATED